Home » 2017 » April
World’s first Malaria Vaccine ready for test in three African Countries

World’s first Malaria Vaccine ready for test in three African Countries

World Health Organization has announced that three African countries: Ghana, Kenya and Malawi are selected for testing the world’s first malaria vaccine next year on young children who were at high risk of death. This malaria vaccine is developed by a pharmaceutical company, GlaxoSmithKline. The funding of $ 49 million for the first phase of […]

Genetech’s lucentis approved by US FDA for diabetic retinopathy treatment

Genentech’s injection to treat diabetic retinopathy, lucentis (ranibizumab injection) has been approved by the U.S. Food and Drug Administration (FDA). The approved dosage of ranibizumab injection to be administered monthly once is 0.3mg for treating all types of diabetic retinopathy. Diabetic Retinopathy Treatment with Lucentis Injection Lucentis FDA approval means that the drug is now […]

Continue reading …
APAC Biotech’s Immuno-oncology drug Apceden gets approved in India

The Indian FDA (CDSCO – Central Drugs Standard Control Organization) has granted a commercial license to APAC Biotech to market Apceden, a Dendritic cell-based autologous Immuno-oncology drug for prostate, ovarian, colo-rectal and non small cell lung carcinoma form of cancers. Following a stringent review of the application submitted by the Indian biotechnology company, the Indian […]

Continue reading …
Neurocrine’s Ingrezza approved by FDA for tardive dyskinesia treatment

The US Food and Drug Administration (FDA) has approved for Ingrezza (valbenazine) capsules developed by Neurocrine Biosciences for the treatment of tardive dyskinesia patients. A selective vesicular monoamine transporter 2 (VMAT2) inhibitor, Ingrezza has become the first drug to be approved by the regulator to treat adults suffering from tardive dyskinesia. VMAT2 is a protein […]

Continue reading …
Genentech MS drug Ocrevus approved by FDA for multiple sclerosis treatment

Roche Group’s subsidiary Genentech has secured the US FDA approval for its multiple sclerosis drug, Ocrevus (ocrelizumab) for treating both relapsing and primary progressive variants of the chronic disease through intravenous infusion. The FDA approval has made the Genentech MS drug Ocrevus as the first and only therapy available for the two forms of multiple […]

Continue reading …
Dupixent eczema injection gets FDA approval for atopic dermatitis treatment

Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Dupixent eczema injection with that has become the first ever biologic medicine approved for atopic dermatitis treatment in patients whose disease is not managed adequately […]

Continue reading …